Cullen Frost Bankers Inc decreased Johnson & Johnson Com (JNJ) stake by 1.74% reported in 2017Q2 SEC filing. Cullen Frost Bankers Inc sold 3,613 shares as Johnson & Johnson Com (JNJ)’s stock rose 6.85%. The Cullen Frost Bankers Inc holds 204,085 shares with $27.00M value, down from 207,698 last quarter. Johnson & Johnson Com now has $378.65B valuation. The stock increased 0.91% or $1.2745 during the last trading session, reaching $140.9445. About 3.11M shares traded. Johnson & Johnson (NYSE:JNJ) has risen 12.54% since December 6, 2016 and is uptrending. It has underperformed by 4.16% the S&P500.
The stock of Abaxis, Inc. (NASDAQ:ABAX) is a huge mover today! The stock increased 2.95% or $1.39 during the last trading session, reaching $48.49. About 65,651 shares traded. Abaxis, Inc. (NASDAQ:ABAX) has risen 7.18% since December 6, 2016 and is uptrending. It has underperformed by 9.52% the S&P500.The move comes after 7 months positive chart setup for the $1.10 billion company. It was reported on Dec, 6 by Barchart.com. We have $52.85 PT which if reached, will make NASDAQ:ABAX worth $99.09 million more.
Investors sentiment decreased to 0.83 in Q2 2017. Its down 0.03, from 0.86 in 2017Q1. It fall, as 50 investors sold JNJ shares while 878 reduced holdings. 105 funds opened positions while 667 raised stakes. 1.73 billion shares or 0.03% less from 1.73 billion shares in 2017Q1 were reported. Cibc World Mkts invested 1.14% of its portfolio in Johnson & Johnson (NYSE:JNJ). Raymond James Finance Serv Advsrs has 0.91% invested in Johnson & Johnson (NYSE:JNJ). Cohen Steers owns 124,318 shares or 0.04% of their US portfolio. Robert Wood Johnson Foundation has invested 100% in Johnson & Johnson (NYSE:JNJ). Holt Advsr Limited Liability Dba Holt Prtnrs Lp owns 1.14% invested in Johnson & Johnson (NYSE:JNJ) for 25,145 shares. 327,100 were accumulated by Berkshire Hathaway. Harding Loevner Ltd Partnership holds 0% or 800 shares in its portfolio. Atalanta Sosnoff Capital Ltd Limited Liability Company has 0.42% invested in Johnson & Johnson (NYSE:JNJ). Kames Public Ltd Co stated it has 0% of its portfolio in Johnson & Johnson (NYSE:JNJ). Advisor Prns Limited Co invested 1.88% of its portfolio in Johnson & Johnson (NYSE:JNJ). Fayerweather Charles holds 5.18% or 29,065 shares. Staley Cap Advisers Inc accumulated 202,201 shares. Regent Management Limited Com invested in 46,617 shares. Rbo And Ltd Liability Corp invested in 219,996 shares. Oakbrook Invs Ltd Llc has 136,124 shares for 1.19% of their portfolio.
Among 23 analysts covering Johnson & Johnson (NYSE:JNJ), 13 have Buy rating, 5 Sell and 5 Hold. Therefore 57% are positive. Johnson & Johnson had 83 analyst reports since August 7, 2015 according to SRatingsIntel. Jefferies maintained Johnson & Johnson (NYSE:JNJ) on Tuesday, March 15 with “Hold” rating. The company was maintained on Monday, October 2 by Piper Jaffray. The stock has “Market Perform” rating by Wells Fargo on Thursday, January 26. On Monday, October 5 the stock rating was reinitiated by Piper Jaffray with “Neutral”. As per Friday, July 21, the company rating was downgraded by Alembic. The company was maintained on Wednesday, October 18 by Barclays Capital. The rating was upgraded by Deutsche Bank to “Buy” on Tuesday, September 29. BMO Capital Markets maintained the shares of JNJ in report on Tuesday, October 17 with “Buy” rating. The stock of Johnson & Johnson (NYSE:JNJ) earned “Buy” rating by RBC Capital Markets on Friday, September 22. RBC Capital Markets maintained Johnson & Johnson (NYSE:JNJ) rating on Wednesday, October 18. RBC Capital Markets has “Buy” rating and $147.0 target.
Cullen Frost Bankers Inc increased Bank Of America Corp Com (NYSE:BAC) stake by 391,808 shares to 495,523 valued at $12.02M in 2017Q2. It also upped Spdr Gold Trust Etf (GLD) stake by 18,294 shares and now owns 36,119 shares. Walgreens Boots Alliance Inc C was raised too.
Analysts await Johnson & Johnson (NYSE:JNJ) to report earnings on January, 23. They expect $1.72 EPS, up 8.86% or $0.14 from last year’s $1.58 per share. JNJ’s profit will be $4.62 billion for 20.49 P/E if the $1.72 EPS becomes a reality. After $1.90 actual EPS reported by Johnson & Johnson for the previous quarter, Wall Street now forecasts -9.47% negative EPS growth.
Investors sentiment decreased to 1.12 in 2017 Q2. Its down 0.31, from 1.43 in 2017Q1. It dropped, as 11 investors sold Abaxis, Inc. shares while 40 reduced holdings. 14 funds opened positions while 43 raised stakes. 21.86 million shares or 0.75% less from 22.02 million shares in 2017Q1 were reported. Voya Management Ltd Liability Corporation reported 0% in Abaxis, Inc. (NASDAQ:ABAX). Raymond James Assocs owns 108,169 shares. Neuberger Berman Limited Liability Company has 0.05% invested in Abaxis, Inc. (NASDAQ:ABAX) for 754,763 shares. State Of Alaska Department Of Revenue accumulated 4,477 shares. Riverhead Cap Mgmt Lc stated it has 1,598 shares or 0% of all its holdings. Bancorp Of America De holds 30,891 shares or 0% of its portfolio. Ltd Liability Corp accumulated 0.04% or 20,700 shares. Swiss Natl Bank holds 0% or 37,100 shares. Louisiana State Employees Retirement System holds 9,200 shares. Legal General Plc reported 44,532 shares. Arizona State Retirement Sys holds 11,834 shares. Susquehanna Int Gp Ltd Liability Partnership reported 0% of its portfolio in Abaxis, Inc. (NASDAQ:ABAX). Brown Capital Management Limited Com reported 2.21% in Abaxis, Inc. (NASDAQ:ABAX). Geode Management Ltd Limited Liability Company has 0% invested in Abaxis, Inc. (NASDAQ:ABAX) for 191,610 shares. Pub Sector Pension Inv Board reported 0.01% stake.
Analysts await Abaxis, Inc. (NASDAQ:ABAX) to report earnings on January, 25. They expect $0.24 earnings per share, down 20.00% or $0.06 from last year’s $0.3 per share. ABAX’s profit will be $5.45 million for 50.51 P/E if the $0.24 EPS becomes a reality. After $0.29 actual earnings per share reported by Abaxis, Inc. for the previous quarter, Wall Street now forecasts -17.24% negative EPS growth.
Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care settings to provide rapid blood constituent measurements for clinicians worldwide. The company has market cap of $1.10 billion. It operates in two divisions, Medical Market and Veterinary Market. It has a 40.75 P/E ratio. The firm offers Piccolo chemistry analyzers with rapid blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.